Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Chiara Pacifico"'
Publikováno v:
Critical Reviews in Oncology/Hematology. 113:18-21
Orteronel (TAK-700) is an oral, non-steroidal 17,20-lyase inhibitor with higher specificity for 17,20 lyase over 17 hydroxylase. The first phase III studies showed an advantage with orteronel compared with placebo in terms of progression free surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31f0f720573daeb269ca5947daa87179
https://doi.org/10.1016/j.critrevonc.2017.02.023
https://doi.org/10.1016/j.critrevonc.2017.02.023
Publikováno v:
Investigational New Drugs. 35:518-523
Ramucirumab is a monoclonal antibody against Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) approved for the treatment of several solid tumours. As shown in recent trials results, new-onset hypertension is one of the most frequent adverse ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6668b4d4f0b126b4bd9a01100291868a
https://doi.org/10.1007/s10637-017-0452-1
https://doi.org/10.1007/s10637-017-0452-1
Autor:
Simon Wigfield, Laura Zanotti, Pierpaolo Correale, A. Guglielmi, Angela Gobbi, Daniele Generali, Chiara Pacifico, Giandomenico Roviello
Publikováno v:
Immunotherapy. 9:25-32
Aim: IL-2 is one of the first immunomodulating cytokines to be tested in the treatment of cancer patients. The effects of this agent in the treatment of solid tumors other than renal cancer and melanoma are poorly understood. Materials & methods: We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fbfd2cadfdf37986ee614eca4ede19d
https://doi.org/10.2217/imt-2016-0107
https://doi.org/10.2217/imt-2016-0107
Autor:
Daniele Generali, Chiara Pacifico, Giandomenico Roviello, Andrea Giovanni Multari, Angela Gobbi, Giulia Borsella, Laura Zanotti, Maria Rosa Cappelletti
Publikováno v:
Critical Reviews in Oncology/Hematology. 108:62-68
Several new biological agents have been investigated as second line of treatment in advanced Hepatocellular Cancer (HCC). We performed a meta -analysis to assess the effect of targeted therapies in advanced HCC patients beyond the first line of treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a16fa4d5d27c2647abf0a2d8dd067686
https://doi.org/10.1016/j.critrevonc.2016.10.015
https://doi.org/10.1016/j.critrevonc.2016.10.015
Autor:
Daniele Marrelli, Giandomenico Roviello, Karol Polom, Andrea Giovanni Multari, Chiara Pacifico, Daniele Generali, Giovanni Paganini, Franco Roviello
Publikováno v:
Cancer investigation. 35(3)
Angiogenesis is a key process in cancer development. We performed a meta-analysis to assess the efficacy and safety of the novel VEGFR-2 inhibitors in patients with metastatic gastric and gastroesophageal junction cancer. A literature-based meta-anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eff8b83a9f9056a8b408591e7f1c8bf
https://pubmed.ncbi.nlm.nih.gov/28165839
https://pubmed.ncbi.nlm.nih.gov/28165839
Yoon et al reported the first randomized, phase II trial of ramucirumab, an anti-vascular endothelial growth factor receptor-2 monoclonal antibody, as front-line therapy in patients with advanced adenocarcinoma of the esophagus or gastric/gastroesoph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e52db6a067b076de4dcdff9aa39c2669
http://hdl.handle.net/11365/1058512
http://hdl.handle.net/11365/1058512
Autor:
Alberto Bonetta, Giandomenico Roviello, Silvia Paola Corona, Gianni Cancarini, Chiara Pacifico, Daniele Generali, Sarah Grazia Brenna
Publikováno v:
The American Journal of Case Reports
Università degli studi di Firenze-IRIS
Università degli studi di Firenze-IRIS
Patient: Male, 58 Final Diagnosis: Prostate cancer Symptoms: Testicular mass Medication: — Clinical Procedure: — Specialty: Oncology Objective: Unusual clinical course Background: Prostatic adenocarcinoma is the most frequently diagnosed carcinom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::807b5898b10aecf85d14002421b33783
http://hdl.handle.net/2158/1156803
http://hdl.handle.net/2158/1156803
Autor:
Giovanni Paganini, Giandomenico Roviello, Chiara Pacifico, Laura Zanotti, Maria Rosa Cappelletti, Angela Gobbi, Raheleh Roudi, Daniele Generali, Martina Dester
EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib changed dramatically the history of metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. However, not enough data are available on the efficacy of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c6e9c8f2ba559d7a25b0e6064a3208
http://hdl.handle.net/11368/2903512
http://hdl.handle.net/11368/2903512
Autor:
Laura Zanotti, Giandomenico Roviello, Maria Rosa Cappelletti, Alberto Bonetta, Martina Dester, Daniele Generali, Angela Gobbi, Chiara Pacifico
Publikováno v:
Clinical genitourinary cancer. 15(3)
Background The aim of the present study was to evaluate the activity and tolerability of low-dose oral ethinylestradiol (EE) and luteinizing hormone-releasing hormone analogue with concomitant low-dose acetylsalicylic acid (ASA) as a thromboprophylac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b2c4b33f94c0e3e719c4afaadeb7fe
https://pubmed.ncbi.nlm.nih.gov/27692697
https://pubmed.ncbi.nlm.nih.gov/27692697